InvestorsHub Logo
Followers 3
Posts 281
Boards Moderated 0
Alias Born 12/21/2022

Re: None

Thursday, 12/14/2023 10:28:19 AM

Thursday, December 14, 2023 10:28:19 AM

Post# of 203
Ryzneuta was approved 3 weeks ago. Second "novel" long-acting G-CSF. Acrotech is going to market it in the US. It is same company that markets five Spectrum drugs.
https://acrotechbiopharma.com/wp-content/uploads/2023/11/Evive-and-Acrotech-Announce-FDA-Approval-of-Ryzneuta.pdf
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ASRT News